Trend Analysis of Public Enthusiasm for COVID-19 Vaccines on Social Media

Herman Lawelai, Anwar Sadat, Ansar Suherman, Agustiyara Agustiyara, Achmad Nurmandi

Abstract


Social media users benefit from advances in information and communication technology. Each user can access and obtain information by using a mobile phone or other communication device connected to the internet. The implementation of the COVID-19 Vaccination is one of the hottest topics discussed on the Twitter social media platform. Therefore, the purpose of this study is to analyze the trend of public interest in the COVID-19 vaccine on Twitter. This study utilizes Twitter data crawled by the Drone Emprit Academic application using the term "Pfizer Vaccine Enthusiasm and Moderna Vaccines". This study examines 170,641 Twitter mentions related to COVID-19 vaccine messages. Based on the findings of this study, the public's response to COVID-19 immunization was 42,963 mentions from August 23, 2021, to April 23, 2022. Based on the findings of this study, Asia, Europe, and the United States factored for the vast bulk of tweets about the COVID-19 vaccination. There were 25,288 (59 percent) mentions of positive emotions, followed by 16,484 (38 percent) comments and 1,191 (3 percent) topics of neutral emotions. This study's findings enable the government to understand the complexities of the widely discussed topic of COVID-19 immunization, which it can utilize to promote policies and enhance service quality.


Full Text:

PDF


DOI: https://doi.org/10.11114/smc.v10i2.5603

Refbacks

  • There are currently no refbacks.


Studies in Media and Communication      ISSN 2325-8071 (Print)   ISSN 2325-808X (Online)

Copyright © Redfame Publishing Inc.

To make sure that you can receive messages from us, please add the 'redfame.com' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.

If you have any questions, please contact: smc@redfame.com

------------------------------------------------------------------------------------------------------------------------------------------------------